166 related articles for article (PubMed ID: 17313476)
1. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
Manz M; Steuerwald M
Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M
Dig Liver Dis; 2006 Jan; 38(1):27-32. PubMed ID: 16311084
[TBL] [Abstract][Full Text] [Related]
4. Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.
Vartany E; Caldwell CA; Trow TK
Heart Lung; 2008; 37(2):153-6. PubMed ID: 18371508
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
[TBL] [Abstract][Full Text] [Related]
6. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
Colomba C; Rubino R; Siracusa L; Mazzola G; Titone L
J Antimicrob Chemother; 2012 Jan; 67(1):249-50. PubMed ID: 21965434
[No Abstract] [Full Text] [Related]
7. [Hepatitis C therapy is not pleasant. Patients must be prepared!].
MMW Fortschr Med; 2003 Jan; 145(3-4):57. PubMed ID: 12619237
[No Abstract] [Full Text] [Related]
8. Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantation.
Ueda Y; Kaido T; Ito T; Ogawa K; Yoshizawa A; Fujimoto Y; Mori A; Miyagawa-Hayashino A; Haga H; Marusawa H; Chiba T; Uemoto S
Transplantation; 2014 Feb; 97(3):344-50. PubMed ID: 24157473
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?
Merli M; Gentili F; Giusto M; Attili AF; Corradini SG; Mennini G; Rossi M; Corsi A; Bianco P
Dig Liver Dis; 2009 May; 41(5):345-9. PubMed ID: 19162574
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
[TBL] [Abstract][Full Text] [Related]
11. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
Dumortier J; Scoazec JY; Chevallier P; Boillot O
J Hepatol; 2004 Apr; 40(4):669-74. PubMed ID: 15030984
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
Kontorinis N; Agarwal K; Elhajj N; Fiel MI; Schiano TD
Liver Transpl; 2006 May; 12(5):827-30. PubMed ID: 16628699
[TBL] [Abstract][Full Text] [Related]
14. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
[TBL] [Abstract][Full Text] [Related]
15. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.
Angelico M; Petrolati A; Lionetti R; Lenci I; Burra P; Donato MF; Merli M; Strazzabosco M; Tisone G
J Hepatol; 2007 Jun; 46(6):1009-17. PubMed ID: 17328985
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation].
Kim BK; Kwon SY; Ko SY; Choe WH; Lee CH; Han HS; Chang SH
Korean J Hepatol; 2008 Dec; 14(4):519-24. PubMed ID: 19119247
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study.
ReViS-TC Study Group
Transplantation; 2011 Aug; 92(3):334-40. PubMed ID: 21659948
[TBL] [Abstract][Full Text] [Related]
18. [Interferon therapy for hepatitis B and C].
Iino S
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():559-63. PubMed ID: 17455681
[No Abstract] [Full Text] [Related]
19. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
Delabaudière C; Lavayssière L; Dörr G; Muscari F; Danjoux M; Sallusto F; Peron JM; Bureau C; Rostaing L; Izopet J; Kamar N
Transpl Int; 2015 Feb; 28(2):255-8. PubMed ID: 25159822
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.
Mukherjee S; Lyden E; McCashland TM; Schafer DF
J Gastroenterol Hepatol; 2005 Feb; 20(2):198-203. PubMed ID: 15683421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
